Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03186833
Other study ID # PB186316
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 6, 2017
Est. completion date December 31, 2018

Study information

Verified date September 2019
Source University Hospitals Coventry and Warwickshire NHS Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study addresses the hypothesis that a gradual build-up in arterial resistance and microvascular endothelial dysfunction due to common comorbidities such as hypertension and diabetes mellitus, on top of age related vascular and cardiac changes (mainly fibrosis and hypertrophy), is responsible for HFpEF. The HFpEF syndrome is commonly seen in elderly subjects (often females) with hypertension and diabetes.

The investigators will investigate the vascular function, cardiovascular performance and myocardial fibrosis in different cohorts of subjects to try and prove this hypothesis. There will be 5 groups of subjects, all ≥ 70 years of age, as follows:

A) Normal healthy volunteers without major comorbidities including hypertension or diabetes B) Patients with hypertension only (without diabetes mellitus) C) Patients with hypertension AND diabetes mellitus D) Patients with HFpEF. E) A parallel group of patients with Heart Failure with reduced Ejection Fraction (HFrEF) group.

Arterial resistance measured by pulse wave velocity will be the primary measure and will be compared between groups A to D. A separate comparison will be made between groups D and E. Other secondary measures will focus on endothelial function (Laser Doppler measurements) and other cardiovascular performance measures (peak VO2 by CPEX, 6-minute walk distance). Bloods samples will be taken for NT-proBNP, high sensitivity Troponin T, Galectin 3 and also stored for testing later for vascular biomarkers.


Description:

The study will be a pathophysiological, single-centre, observational study, in which all 4 groups, including the parallel-group will be investigated in terms of qualitative-, echocardiographic-, arterial resistance, exercise testing (CPEX and 6-MWT), endothelial dysfunction assessment by Laser Doppler and vascular biomarker measurements. We intend to investigate if there is increasing arterial resistance from group "A" to group "D" and a significant difference in arterial resistance between groups "D" and "E" by measuring the PWV.

Primary Outcome Our primary outcome will be a difference in arterial resistance between the groups and the parallel group, as measured by aortic PWV.

Secondary Outcomes

The secondary outcomes are to assess and compare endothelial function and cardiovascular performance in all groups as measured by the following:

- Blood tests: NTproBNP, Galectin-3

- Urinalysis: Albumin, Creatinine and Metabolite profiles ("metabolomics"), related to cardiovascular risk and insulin resistance

- Transthoracic echocardiography (TTE) indices of LV diastolic function, tissue Doppler imaging and strain rate imaging

- Exercise tolerance: 6-minute walk test and a Cardiopulmonary Exercise Test (CPEX)

- Microvascular function: Laser Doppler


Recruitment information / eligibility

Status Completed
Enrollment 85
Est. completion date December 31, 2018
Est. primary completion date December 31, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 70 Years and older
Eligibility Inclusion Criteria:

- Group A: males or females aged > 70 years without major systemic comorbidities (resting blood pressure <140/90 mmHg, no history diabetes mellitus according to WHO criteria).

- Group B: males or females aged >70 years with hypertension, defined as a documented blood pressure of Systolic Blood Pressure (SP >140 mmHg or >90mmHg Diastolic Blood Pressure) without diabetes mellitus and HF defined as: a) relevant symptoms/signs/radiographic findings as indicated by Boston criteria b) need for diuretic therapy.

- Group C: male or female aged > 70 years with diabetes mellitus (defined according to the World Health Organization (WHO)) AND hypertension, without HF defined as: a) relevant symptoms/signs/radiographic findings as indicated by Boston criteria38 b) need for diuretic therapy.

- Group D: male or female aged >70 years with HFPEF, defined as signs and symptoms of HF with LVEF>50% and raised natriuretic peptides (BNP>35pg/ml or NT-proBNP>125pg/ml) along with one other criteria: i) structural heart disease (left atrial enlargement or left ventricular hypertrophy) on TTE, ii) evidence of LV diastolic dysfunction based on ESC Guidelines 2016, or iii) hospitalization with heart failure within 12 months prior to study entry.

- Group E (parallel group): male or female aged >70 years with HFREF, defined as HF with LVEF <40% on TTE)

Exclusion Criteria:

- Acute coronary syndrome (including MI), cardiac surgery, other major CV surgery within 3 months, or urgent percutaneous coronary intervention (PCI) within 30 days of entry.

- Patients who have had an MI, coronary artery bypass graft (CABG) or other event within the 6 months prior to entry unless an echo measurement performed after the event confirms a LVEF =50%.

- Current acute decompensated HF requiring intravenous therapy

- Alternative reason for shortness of breath such as: significant pulmonary disease or severe COPD, haemoglobin (Hb) <10 g/dl, or body mass index (BMI) > 40 kg/m2.

- Severe left-sided valvular heart disease

- Hypotension (systolic BP <100 mm Hg).

- Severe Liver failure

- Primary pulmonary hypertension

- Bedbound/immobile patients

- Chronic renal failure with creatinine of >250 µmol/l

- Significant Peripheral Vascular Disease (PVD), defined as having signs of absent peripheral pulses or reported claudication pain or documented history of PVD

Study Design


Related Conditions & MeSH terms


Intervention

Other:
no intervention
no intervention

Locations

Country Name City State
United Kingdom University Hospital Coventry and Warwickshire Coventry

Sponsors (1)

Lead Sponsor Collaborator
University Hospitals Coventry and Warwickshire NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Arterial stiffness As measured by the Pulse Wave Velocity 30 minutes
Secondary Endothelial function Laser Doppler Flowmetry 15 minutes
Secondary Blood test NT-proBNP 5 minutes
Secondary Blood test, marker of fibrosis Galectin-3 15 minutes
Secondary Transthoracic echocardiography Left ventricular systolic and diastolic function, Left atrial size, Valvular assessments, Tissue Doppler imaging, strain rate imaging 45 minutes
Secondary Exercise Tolerance Cardio-pulmonary exercise 30 minutes
Secondary Urinalysis Albumin, Creatinine and Metabolite profiles ("metabolomics"), related to cardiovascular risk and insulin resistance 10 minutes
See also
  Status Clinical Trial Phase
Recruiting NCT03549559 - Imaging Histone Deacetylase in the Heart N/A
Completed NCT02173548 - Interleukin-1 Blockade in HF With Preserved EF Phase 2
Completed NCT02459626 - Left Ventricular Stiffness vs. Fibrosis Quantification by T1 Mapping in Heart Failure With Preserved Ejection Fraction
Completed NCT03310099 - Unsaturated Fatty Acids Enriched-diet to Improve Cardiorespiratory Fitness, Metabolic Flexibility and Glucose Tolerance in Obese Patients N/A
Completed NCT02638961 - Inspiratory Muscle Training and Functional Electrical Stimulation for Treatment of HFpEF N/A
Completed NCT03871803 - β-blockers Withdrawal in Patients With HFpEF and Chronotropic Incompetence: Effect on Functional Capacity (Preserve-HR) Phase 4
Completed NCT03672591 - Renal Hemodynamics in Patients With HFpEF
Recruiting NCT03620526 - Inhaled Iloprost and Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction Phase 4
Active, not recruiting NCT03624010 - Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients Phase 2
Completed NCT03541603 - Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF Phase 2
Completed NCT03141567 - LYmphangiogenesis FacTors in Heart Failure States
Completed NCT02744339 - Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction Phase 2
Completed NCT03387813 - Hemodynamic-GUIDEd Management of Heart Failure N/A
Completed NCT03289481 - Treatment of HFpEF With Nitrate Supplement Early Phase 1
Terminated NCT03195660 - Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study N/A
Completed NCT03226652 - Heart Function in Patients Assessed for Sleep Apnoea
Completed NCT03966755 - Unsaturated Fatty Acids to Improve Cardiorespiratory Fitness in Obesity and HFpEF N/A
Not yet recruiting NCT04282850 - Ablation Versus Medical Management of Atrial Fibrillation in HFpEF N/A
Recruiting NCT03184311 - High-intensity Interval Training in Heart Failure Patients With Preserved Ejection Fraction N/A
Withdrawn NCT03317314 - Cardiopulmonary Interactions in Patients With Heart Failure